All In Biotech

NDA 022184 · Abbvie

Lumigan

Bimatoprost · Ophthalmic · Prostaglandin Analog

Last checked: Nov 20, 2026Latest source record: Mar 8, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Aug 31, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

147

39 Phase 3, 7 recruiting

FAERS reports

19,414

7,523 serious, 798 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 22, 2024.

LUMIGAN ® (bimatoprost ophthalmic solution) 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. LUMIGAN ® 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. ( 1 )

Mechanism: Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LUMIGAN · BIMATOPROST 0.01% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Bimatoprost" as an intervention, any sponsor and status, largest first.

All 147 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure3,080
  • drug ineffective1,931
  • ocular hyperaemia951
  • eye irritation925
  • fatigue708
  • eye pain681
  • intraocular pressure increased662
  • vision blurred617
  • hypersensitivity580
  • headache574
  • off label use559
  • dyspnoea546

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004101
200573
2006102
2007129
2008139
2009247
2010290
2011398
2012641
2013561
2014616
20151,274
20161,481
20171,423
20181,091
20191,238
20203,926
20212,062
2022781
2023847
2024678
2025743
2026573

Recalls

2 FDA enforcement reports for this application.

  • Oct 19, 2017 · Class III · Terminated

    Failed Impurities/Degradation Specifications.

  • Mar 16, 2017 · Class III · Terminated

    Failed Impurities/Degradation Specifications

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lumigan (Bimatoprost)

2024 spending

$647M

Beneficiaries

336,870

1,407,999 claims

Per beneficiary

$1,921

$96.72 per unit

View as table
YearSpending
2020$633,540,096
2021$668,670,325
2022$701,339,025
2023$697,002,199
2024$647,209,310

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 250 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.